Preclinical Phase 1 GASTRIC, ESOPHAGEAL & PANCREATICt (CLAUDIN 18.2) Auto logous
NCT04467853 RRMM (BCMA) LEGEND-2t Auto logous NCT03090659 IGlobal IUS I China Phase 2 MMt (BCMA) Al logeneic - CAR-NK NCT05498545 MMt (BCMA) A llogeneic - CAR-yo T NCT05376345 NHLt /ALLt (CD19 X CD20 X CD22}t Auto logous
NCT05318963 NCT05292898 Hect (GPC3) Auto logous NCT05352542 The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health authority approval or
become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list. *In collaboration with Janssen, Pharmaceutical
Companies of Johnson & Johnson. tPhase 1 llT in China. :t:IND applications have been cleared by the U.S. FDA. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCMA, B-cell maturation antigen; DLL3, delta-like ligand 3;
GPC3, glypican-3; GCC, guanylyl cyclase C; HCC, hepatocellular carcinoma; llT, investigator-initiated trial; MM, multiple myeloma; ND, newly diagnosed; NHL, non-Hodgkin lymphoma; NSCLC, non small cell lung cancer; RRMM, relapsed or refractory
multiple myeloma; SCLC, small cell lung cancer. Phase 3 RRMM (BCMA)* 1-3 Prior Lines CARTITUDE-4 Autologous NCT04181827 NDMM (BCMA)* Transplant Not Intended CARTITUDE-5 Autologous NCT04923893 NDMM (BCMA)* Transplant Eligible
CARTITUDE-6 Autologous NCT05257083 GASTRIC, ESOPHAGEAL & PANCREATIC* (CLAUDIN 18.2) Autologous SCLC* (DLL3) Autologous NSCLC (GPC3) Auto logous COLORECTAL (GCC) A utologous AML (CLL 1/CD33 ) A llogeneic RRMM
(BCMA)* CARTIFAN-1 Auto logous NCT03758417 RRMM (BCMA)* CARTITUDE-1 Auto logous NCT03548207 MM (BCMA)* CARTITUDE-2 Auto logous NCT04133636